Skip to main content
Qualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. — Investor Relations & Filings

Ticker · QLGN ISIN · US74754R1032 US Professional, scientific and technical activities
Open in API
Filings indexed 618 across all filing types
Latest filing 2019-08-14 Earnings Release
Country US United States of America
Listing US QLGN

About Qualigen Therapeutics, Inc.

https://qlgntx.com/

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company's efforts are directed toward creating therapeutics for both adult and pediatric patients, with a particular emphasis on rare cancers and areas of high unmet medical need. Its development approach combines internal capabilities with collaborations from major cancer research institutions. The company's investigational oncology pipeline includes programs such as QN-302, a Pan-RAS inhibitor platform, and QN-247.

Recent filings

Filing Released Lang Actions
Earnings Release 2019
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The text specifically mentions that the company issued a press release announcing financial results for the three and six months ended June 30, 2019. The document includes the press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length of the document is 4183 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, a document that announces or furnishes a press release with financial results but does not contain the full financial data or analysis should be classified as an Earnings Release (ER).
2019-08-14 English
Capital/Financing Update 2019
Capital/Financing Update Classification · 100% confidence The document is a Form 424B3 prospectus filed pursuant to Rule 424(b)(3) under the Securities Act of 1933. It relates to the sale of common stock by a selling stockholder and includes detailed information about the offering, use of proceeds, risk factors, and corporate information. The document is a registration/prospectus filing for a secondary offering of shares, not a financial report, earnings release, or management discussion. It is specifically a capital markets document related to financing activities and share sales. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication announcement but a full prospectus filing.
2019-08-06 English
Regulatory Filings 2019
Regulatory Filings
2019-08-02 English
Regulatory Filings 2019
Regulatory Filings
2019-08-02 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter from Ritter Pharmaceuticals, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-3. It references a registration statement filing and requests the SEC to make it effective earlier. The document is short (1384 characters) and is a formal communication related to a securities registration process, not a financial report or earnings release. It does not contain financial data or detailed report content but is an official regulatory filing related to capital markets activity. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2019-07-30 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter from Ritter Pharmaceuticals, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It is a formal communication related to the registration process for securities, specifically referencing the Securities Act of 1933 and Rule 461. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory filing related to the registration process rather than a financial report or announcement of results. Given the short length (1384 characters) and the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2019-07-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.